Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pluristem Therapeutics Inc. (PSTI)

1   -0.03 (-2.91%) 07-25 16:00
Open: 1.02 Pre. Close: 1.03
High: 1.0401 Low: 0.9595
Volume: 170,627 Market Cap: 32(M)

Technical analysis

as of: 2022-11-18 4:23:58 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.21     One year: 1.41
Support: Support1: 0.99    Support2: 0.95
Resistance: Resistance1: 1.04    Resistance2: 1.21
Pivot: 1
Moving Average: MA(5): 1     MA(20): 1
MA(100): 1.01     MA(250): 1.45
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 50.2     %D(3): 50.2
RSI: RSI(14): 57.3
52-week: High: 2.76  Low: 0.68
Average Vol(K): 3-Month: 150 (K)  10-Days: 171 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PSTI ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.04 - 1.05 1.05 - 1.05
Low: 0.95 - 0.95 0.95 - 0.96
Close: 0.99 - 1 1 - 1.01

Company Description

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Headline News

Mon, 05 Dec 2022
IoT: How labelling is preceding legislation - TechNative

Sat, 03 Dec 2022
Sex-linked markers in an Australian frog Platyplectrum ornatum (Limnodynastidae) with a small genome and homomorphic sex chromosomes | Scientific Reports - Nature.com

Fri, 25 Nov 2022
New Rules to Aid UK Full Fibre Builds and Network Security Become Law UPDATE - ISPreview.co.uk

Mon, 14 Nov 2022
The UK's Product Security and Telecommunications Infrastructure Bill - Lexology

Fri, 14 Oct 2022
The PSTI Bill will unleash rural connectivity and boost productivity - PoliticsHome

Mon, 25 Jul 2022
Pluristem Therapeutics renames as Pluri - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 32 (M)
% Held by Insiders 2.759e+007 (%)
% Held by Institutions 7.2 (%)
Shares Short 487 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.605e+007
EPS Est Next Qtl -0.1
EPS Est This Year -0.35
EPS Est Next Year -0.35
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -20
Return on Assets (ttm) 212.8
Return on Equity (ttm) -37.4
Qtrly Rev. Growth 234000
Gross Profit (p.s.) 0
Sales Per Share -45.32
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -38 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 1.2

Stock Dividends

Dividend 0
Forward Dividend 391400
Dividend Yield 0%
Dividend Pay Date 2019-07-24
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.